Patent: RE47849
✉ Email this page to a colleague
Summary for Patent: RE47849
Title: | Otologic nanotechnology |
Abstract: | Diagnosing or treating a human ear includes transporting a conjugated nanoparticle or a magnetically responsive nanoparticle into a human\'s middle or inner ear. Otologic nanophoresis includes electrically, magnetically or electromagnetically driving a nanoparticle through a membrane of the ear, including a tympanic membrane, a round window membrane, an oval window membrane, or a circulatory membrane. An otologic diagnostic device includes a nanoparticle conjugated with a material selected from the group consisting of lipids, proteins, growth factors, growth hormones, antioxidants, free radical scavengers, steroid preparations, and metabolically active substances; an otologic therapeutic device includes the same categories of substances and chemotherapeutic drugs. Another otologic composition includes a nanoparticle conjugated with a substance perceptible to magnetic resonance imaging. |
Inventor(s): | Dyer, Jr.; R. Kent (Edmond, OK), Hough; Jack V. D. (Oklahoma City, OK) |
Assignee: | HOUGH EAR INSTITUTE (Oklahoma City, OK) |
Application Number: | 15/494,201 |
Patent Claims: | see list of patent claims |
Details for Patent RE47849
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | 05/05/2004 | ⤷ Try a Trial | 2022-12-18 |
Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | 12/02/2004 | ⤷ Try a Trial | 2022-12-18 |
Amphastar Pharmaceuticals, Inc. | AMPHADASE | hyaluronidase | Injection | 021665 | 10/26/2004 | ⤷ Try a Trial | 2022-12-18 |
Akorn, Inc. | HYDASE | hyaluronidase | Injection | 021716 | 10/25/2005 | ⤷ Try a Trial | 2022-12-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |